[ad_1]
Photo by Pavlo Gonchar (Pavlo Gonchar / Scanpix)
The vaccine, developed jointly by the British pharmaceutical company AstraZeneca and the University of Oxford, is 70% effective according to phase III clinical trials.
According to The Guardian, studies show that the vaccine is effective in people of different ages.
Sarah Gilbert, a professor of virology at Oxford University, says the news will bring the world closer to addressing the crisis of the pandemic and its aftermath.
“We will continue working to provide the authorities with detailed information,” The Guardian quoted the professor in the hope that the international effort would benefit the world.
The 70% efficacy of the Oxford University vaccine is reported in clinical trials in a combination of two different vaccine dosage regimens, one of which was 90% effective and the other 62%.
“We just realized that we had an effective vaccine that would save many lives. One of the dosing regimens we studied could be about 90% effective, and if this dosing regimen were chosen, more people could be vaccinated,” he says Andreč Pollard, a spokesman for Oxford University who heads the vaccine development unit.
VŽ wrote that the vaccine has already been approved by two other developers: the vaccine developed by Pfizer and BioNTech is 95% effective, the companies have already applied to the US Food and Drug Administration for permission to market it. 95% efficacy was also seen in Moderna vaccine studies.
VŽ has already written that the EU has signed agreements for the purchase of hundreds of millions of doses of future vaccines from BioNTech, Purevac, AstraZeneca and Sanofi, and negotiations with Moderna are continuing whether these products can be marketed.
Write a comment
[ad_2]
